Browsing Tag
CGMP manufacturing
1 post
Neurogene (NASDAQ: NGNE) advances Rett syndrome gene therapy with Embolden trial launch and positive pediatric data
Neurogene reports progress on NGN-401 Rett syndrome gene therapy with pivotal trial launch and strong pediatric data. See what’s ahead in 2026.